Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497342 | 0.88 | SLC29A1 (0.35) | — | |
| SCHEMBL16085903 | 0.84 | RNASE1 (0.37) | RNASE1POLBKDM4ESLC6A2 | |
| SCHEMBL2497688 | 0.81 | RNASE1 (0.33) | RNASE1POLB | |
| SCHEMBL2495776 | 0.80 | P2RY6 (0.38) | ADRA2ADRD5P2RY6ADRA2BSIGMAR1 | |
| SCHEMBL16085973 | 0.74 | LMNA (0.39) | ADRA2ADRD5P2RY6ADRA2BSIGMAR1 | |
| SCHEMBL2495318 | 0.70 | ACHE (0.34) | — | |
| SCHEMBL16086287 | 0.69 | TYMS (0.39) | POLBP2RY6 | |
| SCHEMBL2498542 | 0.69 | TK1 (0.42) | — | |
| SCHEMBL16086017 | 0.69 | DNMT1 (0.33) | — | |
| SCHEMBL2497338 | 0.69 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | RNASE1 286/4885POLB 8/4885ADRA2A 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.